Single User License
INR 100365
Site License
INR 200730
Corporate User License
INR 301095

Service Tax Additional

select a format

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500


Request a quote
Request a Customized research
Request for Sample Report

Recent Viewed Reports

Why Ken Reasearch?


While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"

Simcere Pharmaceutical Group-Product Pipeline Review-2015

Simcere Pharmaceutical Group-Product Pipeline Review-2015

  Request for Sample Report

Executive Summary

Simcere Pharmaceutical Group-Product Pipeline Review-2015


Global Markets Direct's, 'Simcere Pharmaceutical Group-Product Pipeline Review-2015', provides an overview of the Simcere Pharmaceutical Group's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Simcere Pharmaceutical Group's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Simcere Pharmaceutical Group including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Simcere Pharmaceutical Group's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Simcere Pharmaceutical Group's pipeline products

Reasons To Buy

Evaluate Simcere Pharmaceutical Group's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Simcere Pharmaceutical Group in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Simcere Pharmaceutical Group's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Simcere Pharmaceutical Group and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Simcere Pharmaceutical Group

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Simcere Pharmaceutical Group and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Simcere Pharmaceutical Group Snapshot 6

Simcere Pharmaceutical Group Overview 6

Key Information 6

Key Facts 6

Simcere Pharmaceutical Group-Research and Development Overview 7

Key Therapeutic Areas 7

Simcere Pharmaceutical Group-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Pipeline Products-Combination Treatment Modalities 12

Pipeline Products-Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

Simcere Pharmaceutical Group-Pipeline Products Glance 15

Simcere Pharmaceutical Group-Late Stage Pipeline Products 15

Phase III Products/Combination Treatment Modalities 15

Simcere Pharmaceutical Group-Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

Simcere Pharmaceutical Group-Early Stage Pipeline Products 18

IND/CTA Filed Products/Combination Treatment Modalities 18

Preclinical Products/Combination Treatment Modalities 19

Discovery Products/Combination Treatment Modalities 20

Simcere Pharmaceutical Group-Drug Profiles 21

bendamustine hydrochloride 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

fluorouracil 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

SIM-071201 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

(irbesartan + amlodipine besylate) 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

APX-003 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

metatinib tromethamine 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

sevacizumab 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

BMS-817378 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

OSI-930 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

SIM-010603 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

BMS-795311 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

SCR-1693 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

SIM-0710 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

SIM-89 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Small Molecule for Cancer 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Simcere Pharmaceutical Group-Pipeline Analysis 36

Simcere Pharmaceutical Group-Pipeline Products by Target 36

Simcere Pharmaceutical Group-Pipeline Products by Route of Administration 38

Simcere Pharmaceutical Group-Pipeline Products by Molecule Type 39

Simcere Pharmaceutical Group-Pipeline Products by Mechanism of Action 40

Simcere Pharmaceutical Group-Recent Pipeline Updates 42

Simcere Pharmaceutical Group-Dormant Projects 45

Simcere Pharmaceutical Group-Locations And Subsidiaries 46

Head Office 46

Other Locations & Subsidiaries 46

Appendix 48

Methodology 48

Coverage 48

Secondary Research 48

Primary Research 48

Expert Panel Validation 48

Contact Us 48

Disclaimer 49

List of Tables

Simcere Pharmaceutical Group, Key Information 6

Simcere Pharmaceutical Group, Key Facts 6

Simcere Pharmaceutical Group-Pipeline by Indication, 2015 9

Simcere Pharmaceutical Group-Pipeline by Stage of Development, 2015 10

Simcere Pharmaceutical Group-Monotherapy Products in Pipeline, 2015 11

Simcere Pharmaceutical Group-Combination Treatment Modalities in Pipeline, 2015 12

Simcere Pharmaceutical Group-Partnered Products in Pipeline, 2015 13

Simcere Pharmaceutical Group-Partnered Products/ Combination Treatment Modalities, 2015 14

Simcere Pharmaceutical Group-Phase III, 2015 15

Simcere Pharmaceutical Group-Phase II, 2015 16

Simcere Pharmaceutical Group-Phase I, 2015 17

Simcere Pharmaceutical Group-IND/CTA Filed, 2015 18

Simcere Pharmaceutical Group-Preclinical, 2015 19

Simcere Pharmaceutical Group-Discovery, 2015 20

Simcere Pharmaceutical Group-Pipeline by Target, 2015 37

Simcere Pharmaceutical Group-Pipeline by Route of Administration, 2015 38

Simcere Pharmaceutical Group-Pipeline by Molecule Type, 2015 39

Simcere Pharmaceutical Group-Pipeline Products by Mechanism of Action, 2015 41

Simcere Pharmaceutical Group-Recent Pipeline Updates, 2015 42

Simcere Pharmaceutical Group-Dormant Developmental Projects,2015 45

Simcere Pharmaceutical Group, Subsidiaries 46

List of Figures

Simcere Pharmaceutical Group-Pipeline by Top 10 Indication, 2015 8

Simcere Pharmaceutical Group-Pipeline by Stage of Development, 2015 10

Simcere Pharmaceutical Group-Monotherapy Products in Pipeline, 2015 11

Simcere Pharmaceutical Group-Partnered Products in Pipeline, 2015 13

Simcere Pharmaceutical Group-Pipeline by Top 10 Target, 2015 36

Simcere Pharmaceutical Group-Pipeline by Top 10 Route of Administration, 2015 38

Simcere Pharmaceutical Group-Pipeline by Top 10 Molecule Type, 2015 39

Simcere Pharmaceutical Group-Pipeline Products by Top 10 Mechanism of Action, 2015 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Current R&D Portfolio of Simcere Pharmaceutical Group; Simcere Pharmaceutical Group - Key Therapeutics; Simcere Pharmaceutical Group - Pipeline Overview and Promising Molecules; Simcere Pharmaceutical Group - News; Simcere Pharmaceutical Group - Latest Updates; Simcere Pharmaceutical Group - Pipeline; Simcere Pharmaceutical Group - Discontinued/Dormant Projects

Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204


Company Brochure

Engage with Us

query [@]